SLU-PP-332
SLU-PP-332 is an experimental small-molecule pan-agonist of estrogen-related receptors used as a preclinical research tool; it is not a peptide.
The short version
- Why people discuss it
- Discussed for endurance, exercise-mimetic effects and fat loss; the supporting experiments are preclinical. Community interest does not establish benefit or a suitable treatment.
- What it is
- SLU-PP-332 is an experimental small-molecule pan-agonist of estrogen-related receptors used as a preclinical research tool; it is not a peptide.
- Biggest caution
- Published exercise and metabolic findings are from cells and animals. They do not establish a human benefit, dose, route, product specification or safety profile.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Oral or sublingual products discussed online
Community reference · Not clinical guidance- Amount
- 250–1,500 mcg
- Frequency
- Once daily
- Duration / phase
- Often 4 weeks or longer
Sparse inconsistent reports; no human trial or validated formulation Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
Explicit 25 g mouse table: 1.25–2.5 mg total/day IP split twice daily, despite conflicting SC intro.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PubMed: preclinical identification of SLU-PP-332 as an ERR pan-agonistExisting research · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27